The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Series B | Alive

Total Raised

$2.21M

About Cenexys

Developer of treatment and prophylaxis of disease, disorders, and conditions associated with senescence. The company develops therapies to clear senescent cells from the body to treat age-related diseases

Cenexys Headquarter Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cenexys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cenexys is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cenexys Patents

Cenexys has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/1/2014

Monoclonal antibodies, Experimental cancer drugs, Ageing, Transcription factors, Clusters of differentiation

Application

Application Date

12/1/2014

Grant Date

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Ageing, Transcription factors, Clusters of differentiation

Status

Application

Latest Cenexys News

Forge Biologics Announces 7 Presentations at the Upcoming Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 2, 2022

5 scientific poster presentations highlight scalable process and analytical developments for AAV manufacturing May 02, 2022 07:00 AM Eastern Daylight Time COLUMBUS, Ohio--( BUSINESS WIRE )--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that it will deliver seven presentations during the upcoming American Society of Gene and Cell Therapy’s (ASGCT) 25th Annual Meeting, taking place May 16-19, 2022, in Washington, D.C. Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics, and David Dismuke, Ph.D., Chief Technical Officer, will give two oral presentations in addition to five manufacturing-focused scientific poster presentations delivered by additional Forge team members. “Finding safer, more efficient, and accurate manufacturing processes are critical for successful AAV manufacturing campaigns, and we are delighted to showcase Forge’s advances over the past year at ASGCT,” said Dr. Miller. “The upcoming presentations highlight how AAV platform process development can accelerate a program from research to clinical stage cGMP manufacturing at large scale, and we are pleased to share analytical assays that can increase confidence in product safety.” SESSION PRESENTATIONS Presenter: Timothy J. Miller, Ph.D., CEO, President, and Co-Founder, Forge Biologics Session: Scientific Symposia, Translating Science into Medicine: Moving from Bench to Startup (Session 1 of 2), Salon G Date and time: Monday, May 16, 2022, 8:48–9:36 a.m. Title: Platform Process Development for AAV Manufacturing Presenter: David Dismuke, Ph.D., Chief Technical Officer, Forge Biologics Session: Industry Interactions, Tools and Technology Forum III, Room 209 Date and time: Wednesday, May 18, 2022, 4:15–4:30 p.m. POSTER PRESENTATIONS Title: Development of a qPCR Assay Targeting Alu Repeat Elements as a More Sensitive Method for the Detection of Residual Host Cell DNA in rAAV Drug Product Presenter/poster: Julie Bartz, Scientist II, Analytical Development (poster board no. M-278) Date and time: Monday, May 16, 2022, 5:30 p.m. Title: Clarification Studies on HEK293 Cell Lysate for AAV Production Presenter/poster: Blake Gursky, Scientist I, Process Development (poster board no. M-281) Date and time: Monday, May 16, 2022, 5:30 p.m. Title: Downstream Process Development for AAV Manufacturing from 1L to 500L Batch Sizes Presenter/poster: Corben Davis, Scientist II, Process Development (poster board no. Tu-264) Date and time: Tuesday, May 17, 2022, 5:30 p.m. Title: Platform Process Development for AAV Production Presenter/poster: Frank Agbogbo, Ph.D., Vice President, Process Development (poster board no. Tu-265) Date and time: Tuesday, May 17, 2022, 5:30 p.m. Title: Transient Transfection and Scale-Up of AAV Production from 1L to 500L in Bioreactors Presenter/poster: Steven Wesel, Associate Director, Process Development (poster board no. Tu-263) Date and time: Tuesday, May 17, 2022, 5:30 p.m. Full abstracts are available on the ASGCT Annual Meeting website , and conference participants can also access posters through the ASGCT website. About Forge Biologics Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com . Contacts

  • What is Cenexys's latest funding round?

    Cenexys's latest funding round is Series B.

  • How much did Cenexys raise?

    Cenexys raised a total of $2.21M.

  • Who are the investors of Cenexys?

    Investors of Cenexys include ARCH Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.